German conglomerate Bayer AG is under increasing pressure to develop a new strategy for handling its Roundup weedkiller litigation following recent US jury verdicts. Over the last three months, the total damage amount from these verdicts has approached $4 billion, leading to a significant slump in Bayer’s shares.
One particularly notable loss was a case in Pennsylvania which resulted in a jury awarding $2.25 billion to a former user of Roundup who traced his cancer diagnosis back to long-term exposure to the herbicide. This latest setback has investors seriously questioning the financial endurance of Bayer, especially concerning the over 50,000 Roundup claims remaining in the US. Allegations in these claims state that Monsanto, a unit of Bayer, concealed the potential cancer risks associated with their product.
According to Markus Manns, a portfolio manager at Union Investment in Frankfurt, settling again is unlikely to halt future lawsuits, with the possibility of another wave of litigation in the next one to two years. Manns shared the concern that the Roundup cases may prove costlier than previously thought and raised doubts about the sufficiency of current legal provisions.
Past efforts by the company, which had set aside $16 billion for resolving more than 150,000 Roundup cases, saw it spend around $10 billion. Its remaining balance is aimed at accommodating newly filed lawsuits and addressing existing ones that rejected previous settlement attempts. However, if Bayer fails to negotiate a new settlement, they might face similar high-stakes jury verdicts every few months.
Further complicating matters is the current distribution of the ongoing Roundup trials across state courts, each operating under different rules and procedures. This differs from the previous situation where the cases involved federal jurisdictions consolidated and presided over by one judge. Lawyers have indicated that this lack of centralization could hamper Bayer’s settlement negotiations.
Still, Bayer remains committed to contesting Roundup cases based on scientific evidence, worldwide regulatory assessments, and a proven success rate at trial. The company insists that they have prepared adequately for the litigation and will not promote mass settlements in cases that starkly contradict the collective weight of the research.
Ever since Bayer acquired Monsanto in 2018, the company’s share value has been on a downward trend, losing about 70% of its value. Bayer had to raise its litigation fund from $11.6 billion in mid-2021 to $16 billion, but lawsuits continue to mount.
The new CEO, Bill Anderson, faces a tough task convincing investors about the company’s ability to contain the litigation while simultaneously dealing with other challenges. The unrelenting Roundup lawsuits cast a cloud of uncertainty over Bayer’s operations.
The legal headaches extend beyond financial figures. Should Bayer choose to maintain its current structure amidst calls for division separation, the company will struggle to raise capital needed to reduce its debt and bolster its pipeline of experimental pharmaceutical products.
Disproportionate verdict sizes recently awarded against Bayer threaten its winning record. Such outcomes force CEO Anderson to consider trimming shareholder dividends or even potential suspension, as suggested by Thibault Boutherin at Morgan Stanley.
The prospect of continual billion-dollar verdicts presents a bleak reality for Bayer, with the final Roundup litigation cost potentially exceeding the $16 billion set aside for this purpose. The company’s repeated legal predicaments might result in a yearly cash outflow of $1 billion to $2 billion for the foreseeable future.
Read the full story here.